BioCryst Pharmaceuticals BCRX Work in process
Work in process at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:InventoryWorkInProcess.
The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioCryst Pharmaceuticals's work in process.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioCryst Pharmaceuticals's work in process?
- BioCryst Pharmaceuticals (BCRX) reported work in process of $20.54M in Q1 2026.
- How has BioCryst Pharmaceuticals's work in process changed year-over-year?
- BioCryst Pharmaceuticals's work in process increased by 17.9% year-over-year, from $17.43M to $20.54M.
- What is the long-term trend for BioCryst Pharmaceuticals's work in process?
- Over 3 years (2022 to 2025), BioCryst Pharmaceuticals's work in process has grown at a -4.9% compound annual growth rate (CAGR), from $14.99M to $12.89M.
- What does work in process mean?
- Partially completed goods currently in the manufacturing process, including materials, labor, and overhead costs incurred to date.